| __timestamp | Blueprint Medicines Corporation | GSK plc |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 8246000000 |
| Thursday, January 1, 2015 | 14456000 | 9232000000 |
| Friday, January 1, 2016 | 19218000 | 9366000000 |
| Sunday, January 1, 2017 | 27986000 | 9672000000 |
| Monday, January 1, 2018 | 47928000 | 9915000000 |
| Tuesday, January 1, 2019 | 96388000 | 11402000000 |
| Wednesday, January 1, 2020 | 157743000 | 11456000000 |
| Friday, January 1, 2021 | 195293000 | 10975000000 |
| Saturday, January 1, 2022 | 237374000 | 8372000000 |
| Sunday, January 1, 2023 | 295141000 | 9385000000 |
| Monday, January 1, 2024 | 359272000 |
Unleashing insights
In the world of pharmaceuticals, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key indicator of a company's growth trajectory. Over the past decade, GSK plc and Blueprint Medicines Corporation have showcased contrasting patterns in their SG&A expenditures. From 2014 to 2023, GSK plc consistently maintained a robust SG&A budget, peaking at approximately $11.5 billion in 2020. This reflects their expansive global operations and commitment to maintaining a competitive edge. In contrast, Blueprint Medicines Corporation, a burgeoning biotech firm, exhibited a remarkable growth in SG&A spending, surging from a modest $7.9 million in 2014 to nearly $295 million by 2023. This 37-fold increase underscores their aggressive expansion strategy and investment in market penetration. As these companies navigate the competitive landscape, their SG&A strategies offer a window into their operational priorities and future ambitions.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Blueprint Medicines Corporation
Breaking Down SG&A Expenses: GSK plc vs Viatris Inc.
Who Optimizes SG&A Costs Better? GSK plc or Protagonist Therapeutics, Inc.
Who Optimizes SG&A Costs Better? GSK plc or Mesoblast Limited
Comparing SG&A Expenses: GSK plc vs Ligand Pharmaceuticals Incorporated Trends and Insights
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Alpine Immune Sciences, Inc.
Blueprint Medicines Corporation and Ultragenyx Pharmaceutical Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation or Amneal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation